Literature DB >> 130746

Lymphocytotoxicity to tumor target cells and interference of serum factors or tumor antigen with lymphocytotoxicity in patients suffering from different stages of breast carcinoma.

H Warnatz, D Lackner, E Eder, F Scheiffarth, M Gruhl, O Bischoff.   

Abstract

The in vitro cytotoxicity of lymphocytes from patients suffering from breast carcinoma against autochthonous, allogeneic and established breast carcinoma cells was evaluated. Lymphocytotoxicity to breast carcinoma cells was observed in all stages of the disease. Control lymphocytes from healthy donors or patients suffering from other carcinoma are not cytotoxic for the breast carcinoma cell lines. A follow-up study of the cell mediated immune reactions before and after surgical removal of the breast carcinoma showed that the cytotoxic lymphocyte population which is demonstrated in the presence of the tumor disappears quickly after excision of the carcinoma. The non-reactivity of lymphocytes is not due to a general immune defect. Serum of the tumor bearers did not block the lymphocytotoxicity in early stage breast carcinoma; in metastatic disease inhibition occurred in more than half of the cases. Preincubation of lymphocytes with antigen preparations of allogeneic breast carcinoma cells did not inhibit the cytotoxicity to breast carcinoma cells whereas autologous serum preincubated with the antigen preparation diminished the lymphocyte reactivity to the target cells in some cases.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 130746     DOI: 10.1007/bf00304951

Source DB:  PubMed          Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol        ISSN: 0084-5353


  22 in total

Review 1.  Immunity to neuroblastomas and melanomas.

Authors:  K E Hellström; I Hellström
Journal:  Annu Rev Med       Date:  1972       Impact factor: 13.739

2.  Tumor-specific antigen solubilized by hypertonic potassium chloride.

Authors:  M S Meltzer; E J Leonard; H J Rapp; T Borsos
Journal:  J Natl Cancer Inst       Date:  1971-09       Impact factor: 13.506

3.  Demonstration of cell-mediated immunity to human neoplasms of various histological types.

Authors:  I Hellström; K E Hellström; H O Sjögren; G A Warner
Journal:  Int J Cancer       Date:  1971-01-15       Impact factor: 7.396

Review 4.  Cytotoxic effects of lymphoid cells in vitro.

Authors:  P Perlmann; G Holm
Journal:  Adv Immunol       Date:  1969       Impact factor: 3.543

5.  Some recent studies on cellular immunity to human melanomas.

Authors:  I Hellström; K E Hellström
Journal:  Fed Proc       Date:  1973-02

6.  Inhibition of lymphocyte cytotoxicity for human colon carcinoma by treatment with solubilized tumour membrane fractions.

Authors:  R W Baldwin; M J Embleton; M R Price
Journal:  Int J Cancer       Date:  1973-07-15       Impact factor: 7.396

7.  Specific killing of tumor cells in vitro in the presence of normal lymphoid cells and sera from hosts immune to the tumor antigens.

Authors:  S Pollack; G Heppner; R J Brawn; K Nelson
Journal:  Int J Cancer       Date:  1972-03-15       Impact factor: 7.396

8.  Cellular immunity to renal carcinomas in man.

Authors:  J Bubeník; J Jakoubková; P Krákora; M Baresová; P Helbich; V Viklický; V Malasková
Journal:  Int J Cancer       Date:  1971-11-15       Impact factor: 7.396

9.  Cellular and humoral immune responses to human urinary bladder carcinomas.

Authors:  J Bubeník; P Perlmann; K Helmstein; G Moberger
Journal:  Int J Cancer       Date:  1970-05-15       Impact factor: 7.396

10.  Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms.

Authors:  I Hellström; H O Sjögren; G Warner; K E Hellström
Journal:  Int J Cancer       Date:  1971-03-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.